OKYO Pharma Ltd — Director's Dealing 2022

May 16, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OKYO Pharma Ltd (OKYO)
CIK: 0001849296
Period of Report: 2022-05-16

Reporting Person: JACOB GARY S (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$0.0653	2029-01-06	Ordinary Shares (40000000)		Direct
Option (right to buy)	$0.0640	2031-08-31	Ordinary Shares (13000000)		Direct

Footnotes

F1: 25% will vest each year on January 7, beginning on January 6, 2021.

F2: 25% will vest each year on January 7, beginning on August 31, 2021.